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Pasteurella multocida toxin is a potent mitogen for cultured Swiss 3T3 cells where it causes an accumulation of inosito’l phosphates and activation 
of protein kinase C. The gene sequence described here coded for a 146 kDa protein. The ORF was preceded by a ribosome binding site and followed 
by a stem loop. There was no evidence for a signal sequence. The gene had a low G + C base ratio which differs from the rest of the Pasteurella 
genome. There was no significant homology with other known proteins, although a motif found in certain bacterial toxins which are ADP-ribosyl 
transferases i present. A recombinant expressing only part of the PMT gene was not mitogenic. 
Mitogen; Toxin; Protein kinase C: Pasteure[ia multoc~da 
I. INTRODUCTION of protein kinase C. The toxin does not increase the 
cellular content of CAMP [t 51. 
Proliferation of eukaryotic cells is controlled by com- 
plex pathways of signal transduction, which when ac- 
tivated lead to cell division. Some of the components of 
this process are known for Swiss 3T3 cells, a model 
system for studying signal transduction [11. Understan- 
ding the molecular mechanisms controlling signal 
transduction in eukaryotic cells is of primary impor- 
tance in explaining cell proliferation and has been great- 
ly aided by the use of bacterial toxins which intervene at 
different stages in the signal transduction process [2,3]. 
A toxin produced by some strains of Puste~re~~~ 
~u~toc~da can reproduce the pig disease atrophic 
rhinitis [4,5]. The main signs of disease are loss of the 
nasal turbinate bones, twisting of the snout and a reduc- 
tion in weight gain [6]. The toxin has been purified 
[7-l l] and the gene has been cloned [12-141. Parenteral 
injection of piglets with recombinant oxin reproduces 
clinical atrophic rhinitis and causes damage to liver and 
kidney, and proliferation of cells in the ureter, bladder 
and turbinate mucosa [12]. 
Characterisation of the mode of action of the toxin 
could assist in discovering new signal transduction 
pathways involved in mitogenesis because the activation 
of protein kinase C alone is not sufficient to elicit a 
mitogenic response [11. The sequence of the toxin could 
identify potentialIy important domains and motifs, and 
hence greatly aid molecular analysis. Whilst sequencing 
the mitogenic toxin gene in this laboratory the sequence 
of toxin genes isolated from P. multocida in other 
laboratories became available [17-191. Consequently, it 
was important to ascertain whether these sequences 
were related to the mitogenic toxin which we have 
described [ 151. The sequence of the mitogenic toxin 
gene is analysed here and compared with the other toxin 
gene sequences; we have also examined the mitogenic 
activity of one of the previously sequenced toxins [ 171. 
2. METHODS AND MATERIALS 
2.1. Strains and growth conditions 
We have recently shown that the P. multocida toxin 
is the most potent mitogen yet identified for cultured 
fibroblasts [15]. The toxin stimulates DNA synthesis 
and cell proliferation as effectively as serum in the 
absence of other synergistic factors [IS]. The toxin 
stimulates the production of inositol phosphates and in- 
creases the phosphorylation of the 80 kDa protein, a 
prominent substrate for protein kinase C in 3T3 cells 
[16]; other proteins are phosphorylated independently 
The E. co/i recombinant TOX2 containing plasmid pAJL 13 and the 
non-toxigenic recombinant containing pAJL14 (121 were grown in L 
broth [20]. P. multocida ssp multocida 45/78 was obtained from the 
National Collection of Type Cultures, Centraf Public Health 
Laboratory, UK (Accession Number NCTC 12178). and was grown 
on Bacto-Tryptose broth [21] at 37°C with agitation. All bacteria 
were stored as cell suspensions at - 7O’C in 12% (v/v) glycerol [20]. 
2.2. Toxin purification and assays for toxicity and miiogenicity 
We have previously described the methods used for purification of 
toxin [S], measurement of toxicity 122,231 and assessing DNA syn- 
thesis and cell proliferation [ 151. 
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CCCTTGACCTAGAGGGGCTTTTTTATTACATCAAAAAAATAAACCCCAAACACTGCGAAT‘TTTGGGGTTTTATTTATAACCAAAATACATTAATATGTT 100 
TATTAAGTAAGCATTATCTTACTTTAGGAATAAACTAACAT~TTATGGAT ATG AAA ACA AAA CAT TTT TTT AAC TCA GAT TTT ACT 190 
Met Lyr Thr Lys His Phc Ph. Asn S.r Asp Ph. Thr 
GTA AAA GGA AAA ACT GCC GAT GAA ATT TTT A‘A AGA TTG TGT ACT GAT CAT CCT GAC RAG CAA TTA ARC AAT GTA 
vai Lys ‘ly Lys s*r Ala Asp Glu Il. Ph. Arq Arq Lau Cys Thr Asp His Pro ASP Lys Gln L." Asn Asn Val 
AAA TG‘ AAA 
tys Trp Lys 
GAA GTT 
Glu Val 
TTT ATT AAT CGT TTT GGT CAG ATG AT‘ CTA GAT 
Ph. Il. Asn Arq Ph. Gly Gln Mst M.t L." Asp 
ACT CCT 
Thr Pro 
AAT 
ASn 
CCG AGA AAG ATT 
Pro Arq Lys Il. 
GTA GAA 
Val GIU 
AAA ATT ATT AAT GAA GGG CTT GAA AAA CAA GGC CTG AAA AAT ATA OAT CCT GAA 
Lys 1le Il. Asn Glu Giy L.” ‘1~ Lys Gin Gly L.” Lys A.- Il. Asp Pro Glu 
AAC 
ACT 
Thr 
A.i-l 
(2) 
ACA TAT TTC AAC 
Thr Tyr Ph. A.,, 
ATT TTT 
Il. Ph. 
TCA TCT TCT GAC AGC TCC GAT GGG AAC GTT TTT CAT TAT ARC TCT TTA TCA GAA TCC TAT CGA GTT ACT ‘AT GCC 
ser ser ser Asp S.r Ser Asp ‘ly A.,, Val Ph. His Tyr Asn Ser L.” Set’ Glu S.1 Tyr Arq Val Thr Asp Ala 
340 
490 
640 
790 
940 
1090 
1240 
1390 
is40 
1.590 
1840 
1990 
2140 
TGC CTA ATG 
Cys Leu Met 
AAT ATT 
Asn Il. 
TTT GTG GAG CGT TAT 
Ph. Val GlU Arg Tyr 
TTT ‘AT OAT 
Ph. Asp Asp 
TGG GAC TTG 
Trp Asp L.u 
CTA AAT 
L.u Asn 
AGC 
s.r 
TTA GCC AGT AAT 
Leu Ala S.r Asn 
GGA ATA 
Gly 110 
TAT TCA GTA GGA AAA GAA GGA GCT TAT TAT CCT GAT CAT GAT TAT GGT 
Tyr Ser Val Gly LyS Glu Gly Al. Tyr Tyr Pro Asp His Asp Tyr Gly 
CCA GAA 
Pro Glu 
TAT 
TY~ 
AAC CCT GTT TGG 
Asn Pro Val Trp 
G‘A CCA 
Gly Pro 
ARC GAA CAA ATT TAC CAT TCT AGA GTG ATT GCA GAT ATC CTT TAT GCT CGC TCC GTA TGG GAT GAA TTT AAA AAA 
Asn Glu ‘In Il. Tyr His Ser Arq Val 11. Ala Asp Il. L.,u Tyr Al. Arg Ser VS3. Trp Asp Glu Ph. Lys tys 
TAC TTC ATG 
Tyr Ph. Met 
GAG TAT TGG CAA AAA TAT GCT CAG CTT TAT ACC GAA ATG TTA TCT GAT ACA TTT CTT GCA 
‘lu Tyr Trp ‘ln Lys Tyr Ala Gln L." Tyr Thr ‘lu Mst L.-J 5.r ASP Thr Ph. L." Ala 
ATG GCT 
N.t Ala 
ATT CAG CAA 
Il. Gin ‘lrl 
TAT ACA 
Tyr Thr 
CGA CAA ACG CTT ACT 
Arg Gln Thr Lau Thr 
GAT GAA GGC 
Asp Glu Gly 
TTT CTT ATG 
Ph. Leu "at 
GTT TGT 
va1 cys 
AAC 
ABll 
ACA TAT TAT GGC 
Thr Tyr Tyr Gly 
AAT AAG 
Asn Lys 
GAA GAA GTT 
Glu ‘lu Val 
CAA ATA ACT CTA CTA GAT ATC TAT GGA TAC CCT TCC ACT 
Gln Il. Thr La" Leu Asp Il. Tyr Gly Tyr Pro 5.x Thr 
GAT ATA 
Asp Il. 
ATT 
Il. 
TGT ATA GAG CAA 
Cys Il. Glu Gln 
AAA ‘GG 
Lys ‘ly 
CTT CCT ACT 
L." Pro Thr 
CCT AAA 
Pr* l‘ys 
GTG ATA CTT TAC ATT 
Val Ile L." Tyr If. 
CCT GGA GGA ACA CAA CCA TTT GTT GAA TTT CTT AAT ACA GAT GAT 
Pro ‘ly Gly Thr Gln Pro Ph. Val Glu Ph. L." Asn Thr Asp Asp 
ia) CGA (2.3) 
CTG AAA CAA TGG ATT GCA T‘G CAT TTA AAA CAT AAC AAA CAT ATG ‘TC GCA TTC CGC AAA CAT TTC TC‘ CTA AAA 
L.u Lys Gin Trp Ile Ala Trp His Lsu Lys Asp Asn Lys His Met Val Ala Ph. Arq Lys His Ph. S.r Lcu Lys 
Arq 
CA& CGT CAG GAA GGA GAA ACG TTT ACA GGT ATA ‘AT AAA GCA CTT CAA TAT ATT GCA GAA GAG TCC CCT GAA TGG 
Gin Arq Gln ‘1~ Gly Glu Thr Ph. Thr Gly Ile Asp Lya Al. L.u Gin Tyr Il. Al. Glu Glu SOT Pro Glu Trp 
CCT GCC AAT AAA TAC ATC CTT TAT AAT CCG ACA CAT TTA GAA ACA ‘AA AAT TTA TTT AAC ATC ATG ATG AAG CGA 
Pro Al. Asn Lys Tyr Il. L.u Tyr Asn Pro Thr His Lsu Glu Thr Glu Asn L.u Ph. Asn Il. Mst M.t Lys Atq 
ACA GAA CAG COG ATG CTT GAA OAT AGT GAT GTA CAG ATT AGA TCA AAT TCA GAA GCT ACC COT GAC TAT ‘CT CTT 
Thr Glu Gln Acq M.t L.u Glu Asp Ser Asp Val Gln Ile Arq 5.1 Am,, Sbr Glu AIA Thr Arq Asp Tyr Al. L." 
TCA TTA CTC GAA ACC TTT ATT TCA CAG TTA TCT GCA ATA GAT ATG TTA GTA CCA GCA GTA GGT ATC CCA ATT AAT 
S.c L." L." GlU Thr Ph. Xl. S.r Gln La" S.r Ala Il. Asp M.t Lou Vi,1 Pro Al. V.1 Gly Il. Pro Il. Asn 
TTT GCC CTA TCA GCT ACA GCA TTA GGA CTT AGC TCG OAT ATT GTA GTT AAT GGA GAT TCA TAT GAA AAG A‘A AAA 
Phe Ala LB" Ser Al. Thr Al. L.u Gly Leu Sar S.t Asp Il. V.1 V.1 Aan Gly Asp S.r Tyr Glu Lys Arq Lys 
TAT GGA ATT ‘GO TCC TTA GTG CAA TCT GCA TTA TTC RCA GGA ATT AAT CTT ATT CCA GTT ATT TCG GAA ACC GCA 
Tyr Gly Il. Gly S.r I." V.l Gin Ser Ala L.u Ph. Thr Gly Il. A." L.” Il. Pro V.l Il. S.r ‘1%~ Thr Ala 
GAA ATT TTA TCT TCT TTC TCT AGA ACA GAA GAA GAT ATT CCA GCT TTT TTC ACT GAA GAA CAA GCT TTA GCT CAA 
Glu Ile LB" S.T S.t: Ph. SOT Arq Thr Glu Glu Asp Il. Pro Ala Phe Ph. Thr Glu Glu Gin Ala L." Ala Gin 
CGC TTT GAA ATA GTA GAA GAA GAA TTA CAT TCT ATC TCA CCT GAT GAT CCT CCT CGA ‘AA ATT ACT GAC GAA AAT 
Arq Phe Glu Il. '7.1 Glu Glu Glu L.u His S.r Il. SBS' Pro Asp Asp Pro Pro Arq Glu Ile Thr Asp Glu Asn 
TTA CAT AAA ATT CGT CTG GTA CGT CTT AAC RAT GAA RAT CAA CCT TTA GTT GTG TTA CGA AGA TTA GGA “A AAT 
Leu His Lys Il. Arq L.u Vel Arq Leu Asn Asn Glu Asn Gln Pro Leu Val Val Lou Arq Arq Leu Gly Gly Asn 
AAA TTT ATC AGA ATC GAG CCT ATA ACA TTC CAG GAA ATA AAA GGT TCT TTA GTA A‘T ‘AA GTT ATA AAT CCA GTG 
Lys Ph. Il. Arq Il. Glu Pro Il. Thr Ph. ‘ln ‘1~ Il. Lys ‘ly 5.r Lo" Val S.r Glu Val Il. Aen Pro Vei 
ACT AAT AAA ACG TAC TAC GTA AGC AAT GCT AAA CTA TTA GGG GGC TCT CCT TAT AGT CCT TTC CGT ATT GGA TTA 
Thr As,, Lys Thr Tyr Tyr "al S.r As,, Ala Lys Lo" Leu Gly Gly Ser Pro Tyr S.r Pro Ph. Arq Il. Gly L." 
GAA GGT GTT TGG ACA CCA GAG GTA TTA AAA GCA AGA GCT TCC GTT ATT GGA AAG CCT ATT GGA GAA TCA TAT AAA 
Glu Gly V.1 Trp Thr Pro Gl" V.1 LB" Lya Ala Arq Ala S.r V.1 Ila Gly Lys Pro Il. Gly Glu SOT Tyr LyS 
AGA ATA TTA GCC AAA CTA CAR AGA ATA CAT AAC AGT AAT ATC TTA ‘AT GAG CGA CAR GGT TTA ATG CAT GAA CTC 
Arq Il. Leu Ala Lyr Lsu Gln Arq Il. His Aen Ser Asn Il. Lcu Asp Glu Arq Gin Gly Leu Met His Glu Leu 
ATG GAG CTT ATT OAT CTT TAT GAA GAA TCG CAA CCT TCT TCA GAG CGT TTG AAT GCT TTT CGT GAA CTG CGT ACT 
Met Glu Leu Il. Asp Leu Tyr Gl" Glu 5.r Gin Pro S.r 5.r Glu Arq Lb" Asn Al. Ph. Arq Glu L.u Arq Thr 
CAR TTA GAA AAA GCG CTT TAT CTT CCT GAA ATG GAA GCA TTA AAA AAA CAA ATA CTA CAG ATT CCT AAC AAA GOT 
Gin Leu Glu Lys Ala L.u Tyr LB" Pro Glu M.t Glu Ala LB" Lys Lys ‘ln Il. L." ‘ln 11s Pro Asn Lys ‘ly 
Fig. 1. Sequence of the toxin gene PMTI. (a) marks the end of the insert in pAJL14. Differences between PMTI and other sequences are shown 
by bases above the PMTl sequence and amino acid changes below. The sequences are: 2 1171; 3 [IX]; 4 [19]. 
inger, and were used according to the manufacturer’s specifications. 
Other chemicals were from BDH. 
2.4. Sequencing strategy 
The insert in pAJL13 was isolated by digestion with HpaII followed 
by gel electrophoresis and elution onto silica gel (Geneclean, Statech). 
It was digested with either A/u1 or SuuIIIA and ligated into M13mp18 
cut with either SmaI or BumHI respectively (prior to ligation the cut 
vector was treated with phosphatase). DNA from isolated phage con- 
taining inserts was purified and sequenced using an Applied 
Biosystems sequencer. This strategy produced about IO discrete short 
lengths of sequence. Since these sequences closely matched parts of 
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TCT GGT FCC GCT CGA TTT TTA CTT CGT ACA GCC ATG AAT GAA ATG GCT GGA AAA ACC AGT GAA AGC ACG GCT GAT 
SOT Gly Ala Ala Arg Phe LOU LOU Arg Thr Ala Met ASn Glu Mot Ala Gly Lys Thr Ser Glu S-r Thr Ala Asp 
TTA ATA CGC TTT GCC TTG CAA GAT ACA GTA ATT TCA GCG CCT TTT CGC GGA TAT GCT GGT GCG ATT CCA GAG GCA 
Leu 110 Arg Ph. Ala Lou Gin Asp Thr Val 110 Ser Ala Pro Ph* Arg Gly Tyr Ala Gly Ala II* Pro Glu Ala 
ATA GAC TTT CCT GTA AAA TAT GTA ATA GAA GAC ATA TCT GTA TTT GAT AAA ATA CAG ACA AAT TAC TOG GAA CTT 
Ile Asp Phe Pro Val Lya Tyr Val 11. Glu Asp 110 5.r Val Pho Asp Lys 110 Gln Thr As” Tyr Trp Glu Lcu 
CGA 12.31 
CCT GCT TAT GAA AGC TGG AAC GAA GGA AGT AAT AGC GCA TTA CTG CCT GGT TTG TTA CGT GAA TCG CAA AGC AAG 
Pro Ala Tyr Glu Ser Tq, Asn Glu Gly Ser Asn Ser Ale Lou Lsu Pro Gly LeU LOU Arg Glu Ser Gln Set Lys 
Arg 
GGC ATG TTA AGT AAG TGT COT ATC ATA GAA AAT AGC CTT TAT ATT GGA CAT AGC TAT GAA GAA ATG TTT TAC AGC 
Gly Met I&U scr Lys Cys Arg Ile 11e Glu Asn Ser Leu Tyr 110 Gly His Ser Tyr Glu Glu Met Phe Tyr Ser 
ATT TCT CCA TAT TCA AAC CAG GTT GGA GGG CCT TAT GAA TTA TAT CCT TTC ACT TTT TTC AGT ATG CTT CAA GAA 
Ile Ser Pro Tyr Ser Asn Gln Val Gly Gly Pro Tyr Glu Leu Tyr Pro Phe Thr Ph. Ph. Ser Met mu Gln Glu 
A (4) 
GTA CAA GGT OAT TTA GGA TTT GAG CAG GCC TTT GCC ACA CGT AAC TTT TTC AAT ACT CTT GTT TCT GAT CGA CTA 
V&l Gln Gly Asp Leu Gly Phe Glu Gln Ala Phe Ala Thr Arg Asn Phm Pha Asn Thr Lsu Val S.r Asp Arg Leu 
TY~ 
TCC TTA ATG GAA AAT ACG ATG TTA CTT ACA GAA AGT TTT GAT TAT ACA CCT TGG GAT GCT ATT TAT GGA CAT ATT 
Ser Leu Met 01” Asn Thr Mat Lcu LQ” Thr Glu Scr Phe Asp Tyr Thr Pro Trp Asp Ala Ile Tyr Gly Asp Ile 
AAT TAT GAT GAA CAA TTT GCT GCA ATG TCT ATT AAT GAA CGC ATA GAA AAA TGT ATG AAT ACC TAT AGA GGT GTG 
As,, Tyr Asp Glu Gln Phs Ala Ala Met Sar Ile Asn Glu Arg 11s Glu LyS Cys Met Asn Thr Tyr Arg Gly Val 
GCA TTC CAA AAC TCT TCA AAA AGT ATT GAC TTT TTC CTA AAT AAT CTA ACC ACA TTC ATT GAT AAT GGA CTA ACC 
Ala Phe Gin Asn Ser Sex Lys Ser Ilc Asp Phe Phe Lou Asn Asn LeU Thr Thr Phs 11s Asp Asn Gly Leu Thr 
GAA ATT GCT ATA TCT GAT TTA CCG TAT GAT ATT GTC CAA CAA GAA ATC TCT CAA TTC TTA CAA GGA AGT AAT GAA 
Glu Ile Ala 11s Ser Asp Leu Pro Tyr Asp Ile Vsl Gin Gln Glo Ilc Ser Gln Phe LFU Gin Gly SeI: Asn Glu 
TGG AAA ACA CTT GAT GCC ATG TTA TTT AAC TTA GAT AAA GGA GAT ATT AAT GGT GCT TTC AGA AAG CTT CTG CAA 
Trp Lys Thr LB” Asp Ala Mat Le” Phe Asn LBU Asp LYS Gly Asp Ile Asn Gly Ala Phe Arg Lys LOU Le” Gln 
TCA GCA AAA GAT AAT AAT ATA AAA TTT AGA GCT ATA GGG CAT TCA CAT ART TCT GTT CCG CCA TTT AAT AAC CCT 
Ser Ala Lys Asp Asn Asn 110 Lys Phc Arg Ala 110 Gly His Ser Asp Asn Ser Val Pro Pro Phe Asn Asn Pro 
TAT AAG TCT TTA TAT TAT AAA GGA AAT ATA ATA GCT GAA GCA ATT GAA AAA CTA GAT CGA GAA GGT CAA AAA TTT 
Tyr Lys Ser Leu Tyr Tyr Lys Gly Asn 11s 110 Ala Glu Ala Ilr Glu Lys LOU Asp Arg Glu Gly Gln Lya Phs 
GTT GTA TTT GCT GAT AGT TCT CTG CTC AAC AGC ACG CCT GGG ACA GGT CGT CCT ATG CCA GGA CTA GTT CAR TAT 
Val Val Phe Ala Asp Ser Ser Le” Le” As,, Ser Thr Pro Gly Thr Gly Arq Pro Met Pro Gly L*u Val Gin Tyr 
TTA AAA ATA CCA GCA ACT GTA GTA GAT AGC GAT GOT GCA TGG CAA TTT CTT CCA GAT GTA GCT TCA AGC AGA GTT 
Leu Lys Ile Pro Ala Thr Val Val Asp Ser Asp Gly Ala Trp Gin Ph. La” Pro Asp Val Ala Sar Sar Arg Val 
CCT ATT GAA GTT ACA GAG TTA GAA AAT TGG CAA GTC TTA ACT CCT CCA CAA GGT AAG ATT CTT GGA TTA AAG CAA 
Pro Ile Glu Vsl Thr Glu Leu Glu A5n Trp Gln Val LB” Thr Pro Pro Gln Gly Lys Ile Leu Gly Le,, Lys Gln 
TTT AAG TTA ACG GCA GGT TTT CCA ACA GAA CAA AGT CGC TTA CCT CTT TTA GAG AAT TCG GTT TCT GAA CAT TTA 
Phe Lys Leu Thr Ala Gly Phs Pro Thr Glu Gln Ser Arg Ls” Pro Lou Leau Glu Asn Sar Val Ser Glu Asp Lau 
AGG GAA GAA TTA ATG CAA AAG ATT GAT GCA ATA AAA AAT GAT GTG AAA ATG AAT AGT TTA GTG TGT ATG GAA GCT 
Arg Glu Glu L.U Mot Gin LyS 110 Asp ADA II- Lya As” Asp V11 Lys Mat As,, Ser L.u Val Cys ,,.t Glu Ale 
GGC TCT TGT GAT TCA GTA AGC CCT AAG GTA GCT GCC CGT CTT AAA GAT ATG GGG TTA GAA GCT GGG ATG G‘T GCT 
Gly Sar Cys Asp SOT Val SOK Pro LYS Val Ala Ala Arg Leu Lys Asp “et Gly LOU Glu Ala Gly “at Gly Ala 
TCT ATT ACC TGG TGG AGA CGT GAA GGC GGG ATG GAA TTT TCA CAT CAG ATG CAT ACT ACT GCT TCC TTT AAA TTT 
Ser Ila Thr Trp Trp Arg Arg Glu Gly Gly net Glu Phe Ser His Gln net His Thr Thr Ala ser Phs Lys Phe 
GCT GGT AAA GAG TTT GCC GTG GAT GCT TCA CAT TTA CAA TTT GTA CAC GAC CAA TTA OAT ACA ACT ATC CTG ATA 
Ala Gly Lys Glu Phe Ala ~a1 Asp Ala Ser His Leu Gin Phe Val His Asp Gin Leu Asp Thr Thr Ile LPU Ile 
CTA CCT GTA GAT GAT TGG GCT TTA GAA ATA GCT CAA AGA AAT CGG GCT ATT AAT CCT TTT GTG GAA TAT GTT AGT 
Leu Pro Val Asp Asp Trp Ala Leu Glu Ile Ala Gln Arg Asn Arg Ala Ile As,, Pro Phe Val Glu Tyr Val Ser 
AAA ACA GGA AAC ATG TTA GCA CTC TTC ATG CCT CCT CTT TTC ACA AAG CCT CGC TTA ACA AGA GCA CTA TAA CTA 
Lys Thr Gly AS” Met LBU Ala LOU Phe Met Pro Pro Lou Pha Thr Lys Pro Arg LB” Thr Arg Ala LB” l 
ATTAAAAACTGTATTAAAGCCTTATATTATAAGGCTTTAATTTTCTTTCAAGAATTATTAAGTAGAAGAATCAAAATCAATGAGATAGATAAAATCAAAT 
GTTATTACCAATACAACTTTCTTAAGTATACTTTTTGAATTTTTTGCGTTAATAAATTTATAATACCCTTAACTCAATAAAAGAAGTTATTGAGAAGTTT 
AAATCTTGTGAGCAAGATGAAGATATAATTTCAGCAATCGATCTTATTAGCGCTTCATATAGAAGGGCTGTGGATGCAGTGGAACAAAGATTCGGTTCTAG 
Fig. I contj~~ed 
: Shine Dalgarno ribosoir binding site _: terminator 
the P. multocidu toxin sequence which had become available [17], a 
differnt strategy was adopted to obtain the full sequence of the 
mitogenic toxin. 
Oligonucleotides based on the available sequence [17] were syn- 
thesised on an Applied Biosystems 381A machine at intervals of about 
200 bases along the gene and these were used for double-stranded se- 
quencing using the Sequenase kit according to the manufacturer‘s in- 
structions. For reasons of safety, most of the sequencing was done us- 
ing a non-toxigenic derivative of the gene (pAJL14) which was created 
by removal of a 394 bp fragment by digestion with NdeI and subse- 
quent religation. Removal of the NdeI fragment induces a frameshift 
2290 
2440 
2590 
2740 
1890 
3040 
3190 
3340 
3490 
3640 
3790 
3940 
4115 
4316 
mutation, resulting in a non-toxigenic onstruct (see below). Plasmid 
pAJL13 was used to obtain the sequence of this fragment, but in a 
containment laboratory. Sequence analysis was carried out using 
UWGCG programs. 
3. RESULTS AND DISCUSSION 
3.1, Sequence of the mifogenic toxin 
The sequence (Fig. 1) contained an open reading 
frame (ORF) starting at base 155, which encode a pro- 
61 
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tein of 1285 amino acids which would have a molecular 
mass of 146 kDa (Fig. 1). This is in accord with the ap- 
parent molecular mass of the mitogenic toxin as 
estimated by SDS-PAGE. The most likely start is the 
methionine shown, since the deduced amino acid se- 
quence from this point is identical to the N-terminal 
amino acid sequence of PMTI [IS] except for one 
residue. The difference is likely to be due to experimen- 
tal error in amino acid sequencing. It has been claimed 
that the N-terminal was blocked [ 17,181. The difference 
may be related to the source of the toxin since one was 
purified from recombinant E. coli (unblocked) and the 
other from P. multocida (blocked). A ribosome binding 
site is immediateIy upstream of the start (Fig. I), but no 
obvious E. coli consensus promoter sequence is present. 
Petersen [ 181 has presented convincing evidence for the 
location of the promoter region. The gene is expressed 
well in E. coli [12], but since little is known about 
Pasteurella gene organisation, it is not clear whether 
promoter sequences which function in E. co/i do so in 
P. m~Ito~ida. There were other methionine residues 
downstream from the presumed start. Although none 
had a good consensus with a ribosome binding site it is 
possible that some of the minor polypeptides produced 
by the recombinant which are antigenically related to 
the toxin [12] might have resulted from initiation at 
these residues. There was a stem loop structure typical 
of a terminator region starting at base 4027. 
There was no evidence for a signal sequence at any of 
the potential start codons, which agrees with the lack of 
secretion from either the native P. multocida or the 
recombinant E. coli. A hydrophobicity plot (Fig. 2) in- 
dicated that the protein might have several domains; in 
particular there was a hydrophobic region between 
amino acids 380 and 470 which was bounded by two 
hydrophilic domains, and the C terminal of the protein 
was also hydrophobic. Experiments with the 
lysosomotrophic agent methylamine, which blocks en- 
try of certain toxins 121, and neutralisation of toxin ac- 
Fig. 2. Hydrophobicity plot of the PMTI protein, catculated using a 
program written by Dr M.E.G. Boursnell. Positive numbers indicate 
hydrophobicity. 
tion by antibody when added early but not late to toxin 
treated cells both indicate that the toxin binds to the cell 
surface, is internalised and subjected to processing in 
endosomal/lysosomal compartments [151, from which 
it presumably exits to exert its biological effects. The 
hydrophobic regions revealed in Fig. 2 are likely to play 
a role in the interaction of the toxin with various 
cellular membranes. 
The DNA and deduced amino acid sequences were 
compared with the sequences on the EMBL, Genbank 
and Swissprot data bases, but no significant homology 
was found. The motif His-Glu-Trp which is common to 
several toxins which ADP-ribosylate their substrate [24] 
was found near the N-terminus of the toxin (Fig. 3). 
The spacing between the amino acids matched precisely 
the His-Glu-Trp motif found in the ADP-ribosylating 
toxins (Fig. 3). Amino acid motifs thought to indicate 
the NAD and protein substrate binding site in the ADP 
ribosylating toxins [25] were not present in this toxin. It 
should be noted that the His-Glu-Trp motif was also 
found in a variety of proteins that are not thought to 
ADP-ribosylate any substrates (unpublished). 
As predicted from the restriction map [12] the gene 
had a low G + C content (35%). Interestingly, the G + 
C content of the Pasteurella genome differs markedly 
from that of the toxin gene, so it is possible that the 
gene has been acquired relatively recently and that there 
might exist a family of closely related mitogenic toxin 
genes in other bacteria. Indeed, recent reports indicate 
that the toxin gene is flanked by phage elements [17], 
may be carried on a prophage [26] and that some 
Salmonella isolates contain part of the Paste~rel~a toxin 
gene [27]. 
3.2. Mitogenicity of P. multocida toxin from another 
isolate 
The sequence (hereafter caIled PMTl) was compared 
to the other P. m~~tocida toxin sequences available 
(PMT2 [17]; PMT3 [lS]; PMT4 [19]). There were 4 dif- 
ferences within the open reading frames of the genes, 
and in each case the PMTl sequence was checked 
P. mltocida toxin His xii Glu I TV 
29 155 160 
Pseudomonas aeruqinosa ETA His jr’6 Glu 4 TrP 
426 553 558 
Corvnebacterium dititheriae DT “15 116 Glu (I T[P 
21 148 153 
sordetella mrtussis Sl His 116 GlU 4 =P 
83 210 215 
Vibrm cholerae CT His I*S Glu ? TIP 
44 170 174 
Escherichia cali LTH His 125 Asp I TKP 
44 170 174 
Fig. 3. Comparison of the His-Glu-Trp motif in PMTl with other tax- 
ins. The data for the other toxins are taken from 1241. The numbers 
between the amino acids indicate the spacing between them; the 
numbers below indicate the position in each protein of the respective 
amino acid. 
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PMT (nglml) Days 
Antiserum (d/ml) Protein (ng/ml) 
Fig. 4. Comparison of the mitogenic activity of PMTl and PMT2. (A) Dose-response curve for the stimulation of DNA synthesis by PMTl (0) 
or PMT2 (a). Cultures of Swiss 3T3 cells were incubated with PMT and DNA synthesis measured as described [15]. Each point is the mean of 
two determinations: 10% foetal bovine serum gave a level of incorporation of 704 x lo3 cpm. (B) PMT2 stimulates reinitiation of growth in con- 
fluent Swiss 3T3 cells. PMT2 was added directly to the medium of Swiss 3T3 cell cultures 6 days after plating to give a final concentration of 10 
ng/ml. 2, 3 and 4 days after this addition, cells from both treated (hatched bars) and untreated (open bars) cultures were trypsinised and counted 
using a Coulter counter. The values shown are mean k SE (n = 5). (C) Dose-response for the inhibition by PMT antiserum (polyclonal 34B) of 
DNA synthesis induced by PMTl (0) or PMT2 (0). Various concentrations of immune serum were incubated with toxin and added to confluent 
quiescent Swiss 3T3 cells as described [15]. Each point is the mean of two determinations: 10% foetal bovine serum gave a level of incorporation 
of 979 x 10’ cpm. (D) Dose-response curve for the stimulation of DNA synthesis by extracts of E. coli transformed with various constructs. Swiss 
3T3 cells were treated as described (151 with various concentrations of HBlOl + pAJLl4 ( q ), HBlOl + pAT153 (4) or HBlOl + pAJLl2 ( n ). 
Each point is the mean of two determinations: 10% foetal bovine serum gave a level of incorporation of 672 x 10’ cpm. 
carefully for errors. There was a single base change bet- 
ween the PMTl and the PMT4 sequences (at base posi- 
tion 2712) which resulted in a conservative amino acid 
substitution. There were 2 differences between the 
PMTl gene and that of the gene for PMT3, at base 
positions 1064 and 2477; both resulted in a change from 
an alanine in PMTl to an arginine residue in PMT3. 
There was one other difference between the sequences 
of PMTl and PMT2 at base position 396. 
These minor differences among the sequences might 
be due to errors in sequencing, or reflect variation 
among isolates. If the latter were true, it was important 
to investigate whether the potent mitogenicity of the 
protein was affected. PMT2, purified from P. 
multocida NCTC12178, and PMTl stimulated DNA 
synthesis with an identical dose-response relationship in 
Swiss 3T3 cells (Fig. 4A); there was a similar toxin- 
induced increase in cell proliferation (Fig. 4B). The 
mitogenic activity of each toxin was completely blocked 
by antibody to PMTl in a concentration dependent 
manner (Fig. 4C). 
One of the recombinants produced in the original 
clone bank contained part of the gene, but did not pro- 
duce toxin active on EBL cells [12]. This recombinant 
produced polypeptide fragments which reacted with an- 
tibody to the toxin. Restriction enzyme analysis and the 
DNA sequence of this plasmid showed that it contained 
the N-terminus of the gene, and should code for amino 
acids l-287 to produce a 33.5 kDa peptide (Fig. 1). A 
crude preparation from this recombinant was unable to 
induce DNA synthesis (Fig. 4D). 
4. CONCLUSIONS 
We report the complete sequence of the mitogenic 
toxin PMTl. The deduced protein sequence did not 
show any significant homology to known sequences 
with the possible exception of a motif found in toxins 
which ADP-ribosylate their substrate. There appear to 
be two hydrophobic domains in the toxin, which could 
play a role in the interaction of the toxin with cellular 
membranes. The sequence was almost identical to other 
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P. muftocida toxin sequences [17-191, and the toxin 
purified from one of these latter strains was as 
mitogenic as PMTI in Swiss 3T3 cells. 
It has been suggested that other bacterial toxin genes 
originally had a eukaryotic origin, and this might also 
be the case for the P. multocida toxin. The toxin might 
then be expected to have an as yet undiscovered 
eukaryotic homologue involved in signal transduction. 
It is to be hoped that analysis of the toxin action will not 
only explain its role in atrophic rhinitis, wlrere it has 
specific effects on bone morphogenesis, but also yield 
important information about new signal transduction 
pathways. 
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